Bevatas 100mg Injection contains bevacizumab, a monoclonal antibody used under specialist medical supervision to manage several advanced cancers. It is supplied as a 100 mg/4 mL solution and is manufactured by Intas Pharmaceuticals. Bevacizumab targets vascular endothelial growth factor (VEGF), a protein that promotes the formation of new blood vessels. By blocking VEGF, treatment can restrict the blood supply that tumors need for growth and may help slow cancer progression.

Cancer treatment requires an individualized plan, and Bevatas 100mg Injection does not represent a universal cure. Your oncologist decides whether this medicine is appropriate based on your cancer type, stage, previous treatments, overall health, and response to therapy. The medicine may be prescribed alone in selected situations or, more commonly, alongside other anticancer treatments.

How Bevatas 100mg Injection Works

Bevatas 100mg Injection works through a targeted anti-angiogenic mechanism. Tumors can stimulate nearby blood vessels to grow toward them, supplying oxygen and nutrients that support tumor growth. VEGF plays an important role in this process. Bevacizumab binds to VEGF and reduces its biological activity, which can inhibit new blood-vessel formation around the tumor.

This approach differs from traditional chemotherapy. Chemotherapy generally affects rapidly dividing cells, whereas bevacizumab specifically interferes with a signaling pathway involved in tumor blood-vessel formation. Doctors may combine these approaches because they can work through different mechanisms.

Conditions It May Treat

Doctors may use Bevatas 100mg Injection as part of treatment plans for several cancers, depending on the specific indication and approved treatment regimen. Reported uses include metastatic colorectal cancer, certain forms of non-small-cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma, persistent or metastatic cervical cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It may also be used in combination regimens for hepatocellular carcinoma under appropriate clinical circumstances.

Because treatment indications can depend on the patient’s diagnosis and accompanying medicines, never select bevacizumab based only on a general product description. Your oncology team should determine the complete treatment regimen.

Administration and Dosage

Bevatas 100mg Injection is administered by a qualified healthcare professional through an intravenous infusion. Patients should never self-inject this medicine. The healthcare team determines the dose, infusion schedule, and treatment duration according to the cancer being treated, body weight or other clinical factors, accompanying medicines, and treatment response.

Medical staff may monitor you during and after infusion, particularly during an initial treatment, because infusion-related reactions can occur. Do not change, delay, or discontinue scheduled treatment without discussing it with your oncologist.

Important Safety Information

Before receiving Bevatas 100mg Injection, tell your doctor about all prescription medicines, over-the-counter products, supplements, allergies, and existing medical conditions. Your doctor should know if you have high blood pressure, cardiovascular problems, bleeding problems, kidney concerns, or other significant health conditions.

Bevacizumab can cause clinically important adverse effects, including hypertension, bleeding, impaired wound healing, gastrointestinal perforation, blood clots, and protein in the urine. Some reactions can become serious and require immediate medical attention. Contact your medical team promptly if you experience severe abdominal pain, significant bleeding, chest pain, sudden weakness, severe headache, breathing difficulties, or other unusual symptoms.

Patients undergoing surgery need special planning. Because bevacizumab can interfere with wound healing, doctors may recommend withholding treatment around major surgery and restarting it only when clinically appropriate and adequate healing has occurred.

Pregnancy and Breastfeeding

Bevatas 100mg Injection can harm a developing fetus. Women who can become pregnant should discuss effective contraception with their healthcare provider before and during treatment and for the recommended period after the final dose. Current product information commonly advises contraception for six months following treatment. Breastfeeding should also be avoided during treatment and for the recommended period after the final dose.

Storage and Handling

Bevatas 100mg Injection requires appropriate refrigerated storage. Available product information specifies storage at 2°C to 8°C and advises against freezing. The vial should also be protected from inappropriate handling and should not be shaken.

Proper cold-chain handling matters because biologic medicines require controlled storage conditions. When ordering, choose a legitimate pharmaceutical supplier that follows appropriate storage, packaging, and transportation procedures.

Why Patients Need Professional Supervision

Bevatas 100mg Injection is a prescription oncology medicine, not a general-purpose injection. Its benefits and risks depend heavily on the patient’s cancer diagnosis and overall treatment plan. An oncologist must assess whether bevacizumab is suitable and monitor treatment throughout therapy.

When purchasing Bevatas 100mg Injection, verify the product name, strength, packaging, expiry information, and storage requirements. Because this medicine requires specialist administration, ordering should support—not replace—professional oncology care.

Common Side Effects

Patients receiving Bevatas 100mg Injection may experience effects such as high blood pressure, weakness, nausea, diarrhea, abdominal discomfort, nosebleeds, or changes in blood counts. Side effects vary between patients and may also result from chemotherapy or other medicines used in the same regimen.

Your healthcare provider can explain which symptoms require routine monitoring and which require urgent evaluation. Do not stop cancer treatment simply because you experience a manageable side effect; contact your oncology team for individualized advice.

Frequently Asked Questions

What is Bevatas 100mg Injection used for?

It contains bevacizumab and is used as part of specialist treatment plans for several advanced cancers, including colorectal, lung, kidney, cervical, ovarian, and other selected cancers.

How does Bevatas 100mg Injection work?

It blocks VEGF, a signaling protein involved in the formation of new blood vessels. This can reduce the blood supply that tumors use to grow.

Is Bevatas 100mg Injection a chemotherapy medicine?

It is an anticancer biologic medicine rather than conventional cytotoxic chemotherapy. Doctors may combine it with chemotherapy or other anticancer medicines.

How is Bevatas 100mg Injection given?

A trained healthcare professional administers it as an intravenous infusion. Patients should not administer it themselves.

Can I use Bevatas 100mg Injection during pregnancy?

No. Bevacizumab may harm an unborn baby. Discuss pregnancy prevention and treatment planning with your oncologist before receiving therapy.